Association between SLCO1B1 rs4149056 and Tegafur–Uracil-Induced Hepatic Dysfunction in Breast Cancer | Zendy

Hidenori Kamio | Zendy; Toshitaka Uchiyama | Zendy; Hitoshi Kanno | Zendy; Yoshiko Onoe | Zendy; Kayoko Saito | Zendy; Shingo Kameoka | Zendy; Takako Kamio | Zendy; Takahiro Okamoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association between SLCO1B1 rs4149056 and Tegafur–Uracil-Induced Hepatic Dysfunction in Breast Cancer

Author(s) -

Hidenori Kamio,

Toshitaka Uchiyama,

Hitoshi Kanno,

Yoshiko Onoe,

Kayoko Saito,

Shingo Kameoka,

Takako Kamio,

Takahiro Okamoto

Publication year - 2019

Publication title -

pharmacogenomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.541

H-Index - 91

eISSN - 1744-8042

pISSN - 1462-2416

DOI - 10.2217/pgs-2018-0100

Subject(s) - slco1b1 , odds ratio , medicine , tegafur , pharmacogenomics , gastroenterology , alanine transaminase , single nucleotide polymorphism , pharmacology , oncology , cancer , chemistry , biochemistry , genotype , gene

Aim: The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur–uracil (UFT)-induced liver dysfunction. Patients & methods: A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics analysis. Results: The first screening revealed the association between five SNPs and UFT-induced hepatic dysfunction. In the second step, SLCO1B1 (rs4149056) was found to be the only SNP associated with UFT treatment-related elevation of aspartate aminotransferase (odds ratio: C/C vs T/T = 7.8, C/T vs T/T = 5.7; p = 0.037) and alanine transaminase (odds ratio: C/C vs T/T = 12.2, C/T vs T/T = 4.1; p = 0.034) levels. Conclusion: The SLCO1B1 polymorphisms are possible predictors of UFT treatment-related hepatic dysfunction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research